Issue of Equity

RNS Number : 4025R
Surgical Innovations Group PLC
03 November 2011

3 November 2011


Surgical Innovations Group plc

("SI" or "the Group")

Issue of Equity


Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, today announces that following the exercise of options by an employee it has issued and allotted 330,000 ordinary shares with an exercise price of 3.5p each on 2 November 2011.

Accordingly Application has been made to the London Stock Exchange for the 330,000 New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur on 9 November 2011. The new ordinary shares rank pari passu with the existing shares of the Company.


Following Admission the total number of ordinary shares in issue will be 395,202,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.

- Ends -


Surgical Innovations Group plc

Doug Liversidge, Non-Executive Chairman

Graham Bowland, Chief Executive Officer

Tel: +44 (0) 113 230 7597


Seymour Pierce Limited

Freddy Crossley

Tel: +44 (0) 20 7107 8000

Sarah Jacobs


Media enquiries:
The Communications Portfolio

Ariane Comstive

Tel: +44 (0) 20 7536 2028

Mob: +44 (0) 7785 922 354

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets. 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 140 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand

Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia. 

OEM and IP

The Group supplies large medical device companies on an OEM basis, collecting sales fees as well as IP license and royalty fees.  Clients include Teleflex Medical, Olympus, Gyrus and CareFusion. 



SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime. 

For more information, see




This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings